Climb Bio, Inc.
CLYM
$1.74
$0.106.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.95% | 11.86% | 197.34% | 156.45% | 188.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.93% | 126.54% | 665.99% | 257.15% | 145.49% |
| Operating Income | -26.93% | -126.54% | -665.99% | -257.15% | -145.49% |
| Income Before Tax | -44.89% | 84.21% | -1,124.57% | -131.15% | -124.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.89% | 84.21% | -1,124.57% | -131.15% | -124.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.89% | 84.21% | -1,124.57% | -131.15% | -124.17% |
| EBIT | -26.93% | -126.54% | -665.99% | -257.15% | -145.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -42.80% | 92.91% | -401.63% | 1.66% | 9.48% |
| Normalized Basic EPS | -42.77% | -20.45% | -399.25% | 0.00% | 4.05% |
| EPS Diluted | -42.80% | 92.91% | -401.63% | 1.66% | 9.48% |
| Normalized Diluted EPS | -42.77% | -20.45% | -399.25% | 0.00% | 4.05% |
| Average Basic Shares Outstanding | 1.48% | 122.69% | 144.09% | 135.09% | 147.55% |
| Average Diluted Shares Outstanding | 1.48% | 122.69% | 144.09% | 135.09% | 147.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |